The Risks and Benefits of Long-term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up

Por Steinberg, MH, McCarthy, WF, Castro, O, Ballas, SK, Armstrong, FD, Smith, W, Ataga, K, Swerdlow, P, Kutlar, A, DeCastro, L, Waclawiw, MA
Publicado em 2010

BCL11A Enhancer Haplotypes and Fetal Hemoglobin in Sickle Cell Anemia: BCL11A Enhancers and HbF

Por Sebastiani, P., Farrell, J.J., Alsultan, A., Wang, S., Edward, H. L., Shappell, H., Bae, H., Milton, J. N., Baldwin, C.T., Al-Rubaish, A.M., Naserullah, Z., Al-Muhanna, F., Alsuliman, A., Patra, P. K., Farrer, L.A., Ngo, D., Vathipadiekal, V., Chui, D.H.K., Al-Ali, A.K., Steinberg, M.H.
Publicado no Blood Cells Mol Dis (2015)